Sabby Management’s NRX Pharmaceuticals NRXP Stock Holding History

Sabby Management’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-35,049	Closed	-$59.2K	–	38
2024 Q3	$59.2K	Buy	+35,049	New	+$70.6K	0.03%	26
2023 Q4	–	Sell	-32,500	Closed	-$84.5K	–	79
2023 Q3	$84.5K	Sell	32,500 -37,473	-54%	-$125K	0.06%	53
2023 Q2	$338K	Buy	+69,973	New	+$421K	0.28%	38
2022 Q3	–	Sell	-20,000	Closed	-$120K	–	132
2022 Q2	$120K	Sell	20,000 -58,247	-74%	-$765K	0.08%	77
2022 Q1	$1.92M	Buy	+78,247	New	+$2.55M	0.29%	23

Other funds holding NRXP

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AFM

Anson Funds Management Dallas, Texas $2.29B AUM 370.24% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Squarepoint New York $85.1B AUM 20.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

OWMIAS

One Wealth Management Investment & Advisory Services Miami Beach, Florida $95.3M AUM 25.31% 1-Year Est. Return

Sabby Management's NRXP Position: Q4 2024 in Review

Sabby Management sold out of NRX Pharmaceuticals (NRXP) in Q4 2024, closing a stake of 35,049 shares — an estimated $59.2K sold.

Sabby Management first reported a position in NRXP in Q1 2022 and held it in 5 quarters. The position peaked at $1.92M in Q1 2022. 25 funds tracked by Wall St. Rank hold NRXP as of Q4 2024.

Sabby Management reported no remaining NRX Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
Sabby Management sold 35,049 NRX Pharmaceuticals shares in Q4 2024, an estimated $59.2K.
Sabby Management first reported a position in NRX Pharmaceuticals in Q1 2022 and held it in 5 quarters.
Sabby Management's NRX Pharmaceuticals position peaked at $1.92M in Q1 2022.
25 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q4 2024.

Based on Sabby Management's 13F filing for Q4 2024, filed 14 Feb 2025.